US2014161825A1PendingUtilityA1

Methods of Treating Acute Myeloid Leukemia by Blocking CD47

67
Assignee: UNIV LELAND STANFORD JUNIORPriority: Jan 15, 2008Filed: Jul 12, 2013Published: Jun 12, 2014
Est. expiryJan 15, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Siddhartha JaiswalIrving L. WeissmanRavindra MajetiMark P. Chao
A61P 35/02A61P 43/00A61P 35/00A61P 25/00A61P 13/10A61P 15/00G01N 33/57505C07K 16/3069A61K 47/6851A61K 47/6867C07K 16/2896A61K 47/6865C07K 16/3038A61K 2039/505C07K 16/3061A61K 47/6863C07K 16/18A61K 47/6869C07K 16/3046C07K 2317/76C07K 16/30A61K 47/6861C07K 16/2803C07K 2317/73A61K 39/39558C07K 2317/31A61K 2039/507C07K 16/3053G01N 2500/04C12N 5/0694C12N 5/0093C07K 2317/24C12Q 2600/136C07K 16/28C07K 2317/75C12Q 1/6886G01N 33/5011C12Q 2600/112
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A method of treating a human subject having a solid tumor cancer, the method comprising:
 administering to the human subject an antibody that prevents the binding of CD47 with SIRPα, at a dose that achieves a depletion of cancer cells of the solid tumor.   
     
     
         17 . The method of  claim 16 , wherein the cancer is a carcinoma. 
     
     
         18 . The method of  claim 17 , wherein the carcinoma is ovarian carcinoma, bladder carcinoma, pancreatic carcinoma, breast carcinoma, colon carcinoma, squamous cell carcinoma, or transitional cell carcinoma. 
     
     
         19 . The method of  claim 17 , wherein the carcinoma is a squamous cell carcinoma. 
     
     
         20 . The method of  claim 19 , wherein the squamous cell carcinoma is of the mouth, throat, larynx, cervix or lung. 
     
     
         21 . The method of  claim 16 , wherein the cancer is a sarcoma. 
     
     
         22 . The method of  claim 16 , wherein the cancer is a melanoma. 
     
     
         23 . The method of  claim 16 , wherein the cancer is a brain tumor. 
     
     
         24 . The method of  claim 23 , wherein the brain tumor is selected from astrocytoma, glioblastoma, medulloblastoma, and meningioma. 
     
     
         25 . A method of treating a human subject having a metastatic cancer, the method comprising:
 administering to the human subject an antibody that prevents the binding of CD47 with SIRPα, at a dose that inhibits metastases and/or formation of micrometastases.   
     
     
         26 . The method of  claim 25 , wherein the metastatic cancer is a carcinoma. 
     
     
         27 . The method of  claim 26 , wherein the carcinoma is ovarian carcinoma, bladder carcinoma, pancreatic carcinoma, breast carcinoma, colon carcinoma, squamous cell carcinoma, or transitional cell carcinoma. 
     
     
         28 . The method of  claim 26 , wherein the carcinoma is a squamous cell carcinoma. 
     
     
         29 . The method of  claim 28 , wherein the squamous cell carcinoma is of the mouth, throat, larynx, cervix or lung. 
     
     
         30 . The method of  claim 25 , wherein the metastatic cancer is a sarcoma. 
     
     
         31 . The method of  claim 25 , wherein the cancer is a melanoma. 
     
     
         32 . The method of  claim 25 , wherein the cancer is a brain tumor. 
     
     
         33 . The method of  claim 32 , wherein the brain tumor is selected from astrocytoma, glioblastoma, medulloblastoma, and meningioma.

Join the waitlist — get patent alerts

Track US2014161825A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.